{"id":"cs1001-fluorouracil-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression (anemia, neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL197201","moleculeType":"Small molecule","molecularWeight":"520.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CS1001 (an anti-PD-L1 monoclonal antibody) restores T-cell-mediated anti-tumor immunity by blocking the PD-L1/PD-1 interaction. When combined with fluorouracil (a pyrimidine antimetabolite) and cisplatin (a platinum-based alkylating agent), the chemotherapy agents provide direct cytotoxic effects while potentially enhancing immunogenicity, creating a synergistic triple-modality approach for solid tumors.","oneSentence":"CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:55.344Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer"},{"name":"Esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04187352","phase":"PHASE3","title":"A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2019-12-19","conditions":"Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":540}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CS1001+ Fluorouracil+Cisplatin","genericName":"CS1001+ Fluorouracil+Cisplatin","companyName":"CStone Pharmaceuticals","companyId":"cstone-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects. Used for Gastric or gastroesophageal junction cancer, Esophageal squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}